Insights and advances in chronic urticaria: a Canadian perspective

Allergy, Asthma & Clinical Immunology

Gordon Sussman⁹  Jacques Hébert⁴  Wayne Gulliver⁵  Charles Lynde⁹  Susan Waserman⁸  Amin Kanani³  Moshe Ben-Shoshan⁷  Spencer Horemans⁹  Carly Barron⁹  Stephen Betschel⁹  William H Yang²  Jan Dutz³  Neil Shear⁹  Gina Lacuesta⁶  Peter Vadas⁹  Kenneth Kobayashi²  Hermenio Lima⁸  F Estelle R Simons¹ 

[1] University of Manitoba, Medicine, Winnipeg, MB, Canada

[2] University of Ottawa, Medicine, Ottawa, ON, Canada

[3] University of British Columbia, Medicine, Kelowna, BC, Canada

[4] Université Laval, Medicine, Quebec, QC, Canada

[5] Memorial University, Medicine, Quebec, QC, Canada

[6] Dalhousie University, Medicine, Halifax, NS, Canada

[7] McGill University, Medicine, Montreal, QC, Canada

[8] McMaster University Medicine, Hamilton, ON, Canada

[9] University of Toronto, Medicine, Toronto, ON, Canada

关键词: Omalizumab;    Up-dosing;    Antihistamines;    Immunology;    Management;    Classification;    Diagnosis;    Chronic urticaria;   

Others  :  1128505
DOI  :  10.1186/s13223-015-0072-2

 received in 2014-12-06, accepted in 2015-01-14,  发布年份 2015

【 摘 要 】

In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.

【 授权许可】

   
2015 Sussman et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Maurer M, Bindslev-Jensen C, Gimenez-Arnau A, Godse K, Grattan CEM, Hide M, et al.: Chronic idiopathic urticaria is no longer idiopathic: time for an update! Br J Dermatol 2013, 168:455-456.
• [2]Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al.: The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria: the 2013 revision and update. Allergy 2014, 69:868-887.
• [3]Bernstein J, Lang D, Khan D, Craig T, Dreyfus D, Hsieh F, et al.: The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014, 133:1270-1277.
• [4]Uguz F, Engin B, Yilmaz EJ: Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria. J Psychosom Res 2008, 64:225-229.
• [5]Staubach P, Eckhardt-Henn A, Dechene M, Vovend A, Metz M, Magerl M, et al.: Quality of life in patients with chronic urticarial is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006, 154:294-298.
• [6]Ben-Shoshan M, Blinderman I, Raz A: Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy 2013, 68:131-141.
• [7]Rabelo-Filardi R, Daltro-Oliveira R, Campos RA: Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol 2013, 161:197-204.
• [8]Baiardini I, Pasquali M, Braido F, Fumagali F, Guerra L, Compalati E, et al.: A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005, 60:1073-1078.
• [9]Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al.: Development, validation and initial results of the Angioedema Activity Score. Allergy 2013, 68:1185-1192.
• [10]Weller K, Groffik A, Church M, Hawro T, Krause K, Metz M, et al.: Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014, 133:1365-1372.
• [11]Simons FER, Simons KJ: Histamine and H1-antihistamines: celebrating a century of progress. J Allergy ClinImmunol 2011, 128:1139-1150.
• [12]Kavosh ER, Khan DA: Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J ClinDermatol 2011, 12:361-376.
• [13]Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy ClinImmunol 2010, 125:676-682.
• [14]Weller K, Ardelean E, Scholz E, Martus E, Zuberbier T, Maurer M: Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013, 93:168-174.
• [15]Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol 2013, 23:141-144.
• [16]Church MK, Maurer M, Simons FER, Bindsley-Jensen C, van Cauwenberge P, Bousquet J, et al.: Risks of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 2010, 65:459-466.
• [17]Khan DA: Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy ClinImmunol Pract 2013, 1:433-440.
• [18]Fedorowicz Z, van Zuuren EJ, Hu N: Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012, 3:CD008596.
• [19]Asero R, Tedeschi A: Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2010, 20:386-390.
• [20]Maurer M, Rosen K, Hsieh Hsin J, Saini S, Grattan C, Gimenez-Arnau A, et al.: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013, 368:924-935.
• [21]Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al.: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy ClinImmunol 2013, 132:101-109.
• [22]Sussman G, Hebert J, Barron C, Bian J, Caron-Guay R-M, Laflamme S, et al.: Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014, 112:170-174.
• [23]Saini SS, Bindsley-Jensen C, Maurer M, Grob JJ, Bulbul Baskan E, Bradley MS, et al. Efficacy and safety of Omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: A randomized, placebo-controlled study. J Invest Dermatol 2014;in press.
• [24]Lang DM: A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema. Ann Allergy Asthma Immunol 2014, 112:276-279.
• [25]Metz M, Ohanyan T, Church MK, Maurer M: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014, 150:288-290.